Investigational drug · Phase 3
d-MAPPS
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for oGVHD, Ocular Graft Versus Host Disease, oGHVD.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "d-MAPPS"
First trial start
2025
Jan 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "d-MAPPS", any sponsor or status.
Conditions studied
As listed on its trial records.
- oGVHD
- Ocular Graft Versus Host Disease
- oGHVD
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "d-MAPPS" as an intervention, largest first.
- Study of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD)Pivotal-lookingRecruiting
Regenerative Ocular Immunobiologics LLCIndustry
NCT07776210 · 30 participants (planned) · Start Sep 8, 2026 · Primary completion Mar 31, 2027
Drug: d-MAPPS™ Ophthalmic Solution; Matching vehicle control · For: oGVHD; Ocular Graft Versus Host Disease
Sites: Beverly Hills, California; Palm Harbor, Florida; Boston, Massachusetts · 5 sites in all
- Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)Active, not recruiting
Regenerative Ocular Immunobiologics LLCIndustry
NCT06852768 · 15 participants (planned) · Start Jan 10, 2025 · Primary completion Dec 2026
Drug: d-MAPPS; Placebo · For: oGHVD
Sites: Beverly Hills, California; Huntington Beach, California; Palm Harbor, Florida · 6 sites in all
Regenerative Ocular Immunobiologics LLCIndustry
NCT07210619
Drug: d-MAPPS · For: oGVHD
Newest research
PubMed records naming it or its code names, newest first.
- Ion Channels as Potential Drug Targets in Dry Eye Disease and Their Clinical Relevance: A Review.
Harrell CR, Volarevic V · Cells 2024
- Therapeutic Potential of d-MAPPSࡊ for Ocular Inflammatory Diseases and Regeneration of Injured Corneal and Retinal Tissue.
Harrell CR · Int J Mol Sci 2022
- "Derived Multiple Allogeneic Protein Paracrine Signaling (d-MAPPS)" Enhances T Cell-Driven Immune Response to Murine Mammary Carcinoma.
Harrell CR, Pavlovic D, Miloradovic D, et al. · Anal Cell Pathol (Amst) 2022
- Molecular and Cellular Mechanisms Responsible for Beneficial Effects of Mesenchymal Stem Cell-Derived Product "Exo-d-MAPPS" in Attenuation of Chronic Airway Inflammation.
Harrell CR, Miloradovic D, Sadikot R, et al. · Anal Cell Pathol (Amst) 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.